James T. Coates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James T. Coates has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Bardia
University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA
25 shared publications - Dejan Juric
Harvard Medical School, Boston, USA
25 shared publications - Leif W. Ellisen
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA
25 shared publications - Nayana Thimmiah
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. 1
25 shared publications - Steven J. Isakoff
Harvard Medical School, Boston, USA
25 shared publications - Aiko Nagayama
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, USA
23 shared publications
Latest Publications
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Supplementary Figure S3: COSORT diagram
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Supplementary Figure S3: COSORT diagram
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S6: Proportion of patients achieving Objective Response (OR), per RECIST, with SG and Talazoparib combination in the phase 1b clinical trial, stratified by biomarkers
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S6: Proportion of patients achieving Objective Response (OR), per RECIST, with SG and Talazoparib combination in the phase 1b clinical trial, stratified by biomarkers
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S7. Representativeness of Study Participants
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S7. Representativeness of Study Participants
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S5: Treatment Efficacy with SG and Talazoparib combination in the phase 1b clinical trial
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S5: Treatment Efficacy with SG and Talazoparib combination in the phase 1b clinical trial
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Figure S1. Schematic illustrating proposed temporal window created by SG-mediated drug delivery to enable sequential TOP1i/PARP1i dosing
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Figure S1. Schematic illustrating proposed temporal window created by SG-mediated drug delivery to enable sequential TOP1i/PARP1i dosing
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S5: Treatment Efficacy with SG and Talazoparib combination in the phase 1b clinical trial
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S5: Treatment Efficacy with SG and Talazoparib combination in the phase 1b clinical trial
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S4: Concurrent and sequential dose levels
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S4: Concurrent and sequential dose levels
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Figure S2. Concurrent vs. sequential SG/talazoparib (TZP) in normal and tumor cells
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Figure S2. Concurrent vs. sequential SG/talazoparib (TZP) in normal and tumor cells
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Figure S4. Results of phase 1b clinical trial of SG and talazoparib
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Figure S4. Results of phase 1b clinical trial of SG and talazoparib
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S2: Adverse Effects with SG and Talazoparib combination in the phase 1b clinical trial
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Table S2: Adverse Effects with SG and Talazoparib combination in the phase 1b clinical trial